Clinical Trials · NCT00763451
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 484
- Start date
- Sep 2008
- Locations
- 15 sites, 15 countries
- Primary endpoint
- Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24